Any lingering doubts over the benefit of using AstraZeneca PLC’s third-generation EGFR inhibitor Tagrisso (osimertinib) in stage IB-IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer appear to have been laid to rest with overall survival from the ADAURA study showing it reduced the risk of death by 51% at five years after initial surgery. The data are expected to drive increased EFGR testing, reimbursement and prescribing of the product, firmly embedding it into treatment practice in the adjuvant setting.
ADAURA Survival Boost For AZ’s Tagrisso
More EGFR Testing Needed
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.
